Sugi Predict

Sugi Predict / Compounds / SCHEMBL1265003

SCHEMBL1265003

SCHEMBL1265003

CN1CCN(C(=O)c2cc(N)cc(C(F)(F)F)c2)CC1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HIF1A Q16665 1/20 0.63
▸ CYP3A4 P08684 3/20 0.53
▸ USP2 O75604 3/20 0.53
▸ TSHR P16473 3/20 0.53
▸ CYP2C19 P33261 1/20 0.53
▸ EPHX2 P34913 2/20 0.52
▸ KDM4E B2RXH2 1/20 0.51
▸ KCNH2 Q12809 2/20 0.51
▸ HPGD P15428 2/20 0.49
▸ ALOX15 P16050 1/20 0.49
▸ MEN1 O00255 1/20 0.48
▸ KMT2A Q03164 1/20 0.48
▸ HRH4 Q9H3N8 2/20 0.47
▸ L3MBTL1 Q9Y468 1/20 0.47
▸ CYP2C9 P11712 2/20 0.46
▸ POLB P06746 2/20 0.46
▸ LMNA P02545 1/20 0.46
▸ RHOC P08134 1/20 0.45
▸ RHOA P61586 1/20 0.45
▸ CYP1A2 P05177 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4929358 0.87 KDM4E (0.65) HIF1ACYP3A4USP2TSHRCYP2C19
SCHEMBL13243072 0.87 KDM4E (0.70) HIF1ACYP3A4USP2TSHRCYP2C19
SCHEMBL3172689 0.85 TSHR (0.49) HIF1ACYP3A4USP2TSHRCYP2C19
SCHEMBL4933938 0.85 EPHX2 (0.55) HIF1ACYP3A4USP2TSHRCYP2C19
SCHEMBL12382105 0.84 HIF1A (0.51) HIF1ACYP3A4USP2TSHRCYP2C19
SCHEMBL427055 0.84 HIF1A (0.64) HIF1ACYP3A4USP2TSHRCYP2C19
SCHEMBL1013250 0.83 EPHX2 (0.52) HIF1ACYP3A4USP2TSHREPHX2
SCHEMBL30584223 0.83 EPHX2 (0.52) HIF1ACYP3A4USP2TSHREPHX2
SCHEMBL13219880 0.83 KDM4E (0.51) HIF1ACYP3A4USP2TSHRCYP2C19
SCHEMBL447435 0.83 STS (0.49) HIF1ACYP3A4USP2TSHRCYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4313972-B1 INDOLINE DERIVATIVES AS DDRS INHIBITORS CHIESI FARM SPA (IT) 2025-01-29 — — EP disclosed
US-20240217967-A1 INDOLINE DERIVATIVES AS DDRS INHIBITORS CHIESI FARMACEUTICI S.P.A. (IT) 2024-07-04 — — US disclosed
US-20240217967-A1 INDOLINE DERIVATIVES AS DDRS INHIBITORS CHIESI FARMACEUTICI S.P.A. (IT) 2024-07-04 — — US disclosed
US-20240217967-A1 INDOLINE DERIVATIVES AS DDRS INHIBITORS CHIESI FARMACEUTICI S.P.A. (IT) 2024-07-04 — — US disclosed
EP-1836174-B2 ARYL NITROGEN-CONTAINING BICYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS AMGEN INC (US) 2019-10-02 — — EP disclosed
EP-1836174-B2 ARYL NITROGEN-CONTAINING BICYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS AMGEN INC (US) 2019-10-02 — — EP disclosed
EP-1751136-B1 NITROGENATED HETEROCYCLIC DERIVATIVES AS PROTEIN KINASE MODULATORS AND USE FOR THE TREATMENT OF ANGIOGENESIS AND CANCER AMGEN INC (US) 2014-07-02 — — EP disclosed
EP-1751136-B1 NITROGENATED HETEROCYCLIC DERIVATIVES AS PROTEIN KINASE MODULATORS AND USE FOR THE TREATMENT OF ANGIOGENESIS AND CANCER AMGEN INC (US) 2014-07-02 — — EP disclosed
US-8609656-B2 Heteroarylphenylurea derivative CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2013-12-17 — — US disclosed
US-8557996-B2 Heteroaryl-substituted alkyne compounds and method of use AMGEN INC. (US) 2013-10-15 — — US disclosed
US-20070054916-A1 Aryl nitrogen-containing bicyclic compounds and methods of use AMGEN INC. 2007-03-08 — — US disclosed
US-20070054916-A1 Aryl nitrogen-containing bicyclic compounds and methods of use AMGEN INC. 2007-03-08 — — US disclosed
EP-1724258-A1 HETEROARYLPHENYLUREA DERIVATIVE CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2006-11-22 — — EP disclosed
US-20060241115-A1 Compounds and methods of use AMGEN INC. 2006-10-26 — — US disclosed
EP-1713484-A2 COMPOUNDS AND METHODS OF USE AMGEN INC. (US) 2006-10-25 — — EP disclosed
US-20060217380-A1 Heteroaryl-substituted alkyne compounds and method of use AMGEN INC. 2006-09-28 — — US disclosed
EP-1689376-A2 DIARYL UREA DERIVATIVES IN THE TREATMENT OF PROTEIN KINASE DEPENDENT DISEASES Novartis AG (CH) 2006-08-16 — — EP disclosed
US-20060009453-A1 Protein kinase modulators and method of use AMGEN INC. 2006-01-12 — — US disclosed
WO-2005070891-A2 COMPOUNDS AND METHODS OF USE AMGEN INC (US) 2005-08-04 — — WO disclosed
WO-2005051366-A2 DIARYL UREA DERIVATIVES IN THE TREATMENT OF PROTEIN KINASE DEPENDENT DISEASES NOVARTIS AG (CH) 2005-06-09 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060241115-A1 Compounds and methods of use HGF, HGFAC, MET HIF1A 311/4885CYP3A4 348/4885USP2 4226/4885
US-20060009453-A1 Protein kinase modulators and method of use PHKG1, PRKCH, BMP2K HIF1A 534/4885CYP3A4 2722/4885USP2 2908/4885
US-20060217380-A1 Heteroaryl-substituted alkyne compounds and method of use IRAK3, IRAK1, MAP3K1 HIF1A 904/4885CYP3A4 413/4885USP2 3082/4885
US-20240217967-A1 INDOLINE DERIVATIVES AS DDRS INHIBITORS DDR1, DDR2, DDRGK1 HIF1A 3247/4885CYP3A4 4869/4885USP2 3525/4885
US-20070054916-A1 Aryl nitrogen-containing bicyclic compounds and methods of use MAP3K1, MAP3K5, MAP3K2 HIF1A 480/4885CYP3A4 622/4885USP2 3080/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.